- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.6MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 1.3MB)
Tepotinib – March 2022
Tepotinib: Tablet 225 mg (as hydrochloride monohydrate); Tepmetko®
Last updated
2 August 2022